0QBO.LSE Coloplast A/S
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Dec 2022.
Is 0QBO.LSE undervalued?
Graham numberThe Graham number of Coloplast A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Coloplast A/S fundamental analysis
No fundamental analysis for Coloplast A/S yet.
Coloplast A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of osto…
Full company profileColoplast A/S financial statements
2022 annualized: Fiscal year 2022 is not finished. Income statement and cash flow are annualized from 1 quarter up to Dec 31, 2022, the balance sheet is the latest quarter. Figures change when the annual report is published.
Coloplast A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 15.5B | 16.4B | 17.9B | 18.5B | 19.4B | - | - |
| Gross Profit | 10.6B | 11.1B | 12.2B | 12.6B | 13.3B | - | - |
| Operating Income | 5.02B | 5.09B | 5.16B | 5.85B | 6.16B | - | - |
| Net Income | 3.80B | 3.85B | 3.87B | 4.20B | 4.83B | - | - |
| Balance Sheet | |||||||
| Total Assets | 12.1B | 11.8B | 12.7B | 13.5B | 15.8B | - | - |
| Total Liabilities | 6.10B | 5.35B | 5.82B | 6.09B | 7.67B | - | - |
| Shareholders' Equity | 5.95B | 6.42B | 6.91B | 7.41B | 8.17B | - | - |
| Cash & Short-term Investments | 629M | 607M | 669M | 585M | 674M | - | - |
| Total Debt | 98.0M | 91.0M | 134M | 430M | 449M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 3.25B | 4.36B | 4.36B | 4.76B | 5.29B | 5.10B | - |
| Capital Expenditure | 685M | 616M | 617M | 846M | 919M | 927M | 0.00 |
| Ratios | |||||||
| ROE | 63.8% | 59.9% | 56.0% | 56.7% | 59.1% | - | - |
| ROA | 31.5% | 32.7% | 30.4% | 31.1% | 30.5% | - | - |
| Net Profit Margin | 24.5% | 23.4% | 21.6% | 22.6% | 24.8% | - | - |
| Debt to Equity | 0.02x | 0.01x | 0.02x | 0.06x | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Coloplast A/S dividends
Coloplast A/S has not paid dividends in the last 8 fiscal years.
Last stock split: 5:1 on Dec 19, 2012.
Who owns Coloplast A/S
- Insiders 29.80%
- Institutions 29.44%
- Public & others 40.77%
- Free float 145M
Coloplast A/S company profile
- Company name
- Coloplast A/S
- Ticker
- 0QBO.LSE
- ISIN
- DK0060448595
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 17,213
- Fiscal year end
- December
- Address
- Holtedam 1-3, Humlebæk, Denmark, 3050
- Phone
- 45 49 11 11 11
- Website
- coloplast.com
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Coloplast A/S management
10- Mr. Anders Lonning-SkovgaardExecutive VP & CFO · born 1972
- Mr. Allan RasmussenExecutive Vice President of Global Operations · born 1967
- Mr. Nicolai Buhl AndersenExecutive Vice President of Chronic Care · born 1969
- Mr. Thomas BarfodSenior Controller & Employees Representative Director · born 1970
- Mr. Gavin WoodPresident & CEO · born 1971
- Aleksandra DimovskaVice President of Investor Relations
- Mr. Dennis KaysenVice President of Corporate Communications
- Ms. Amanda RajkumarExecutive VP & Chief People Officer · born 1972
- Mr. Alain MorvanSenior Vice President of Sales Europe
- Ms. Caroline Vagner RosenstandExecutive Vice President of Chronic Care Commercial · born 1979